Substance

ID:182720

Names and Identifiers
IUPAC name
(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid
Synonyms
PGE2Prostaglandin E2(5Z,11α,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acidDinoprostone
IUPAC Traditional name
dinoprostone
Registration numbers
MDL Number
CAS Number
EC Number
Beilstein Number
PubChem SID
Properties
Product Information
Purity
≥93% (HPLC)
Suitability
suitable for cell culture
Biological Source
synthetic
Potency
0.25-100 ng/mL
Safety Information
GHS Hazard statements
H302-H360
GHS Pictograms
GHS07
Acute toxicity (oral, dermal, inhalation), category 4
Skin irritation, category 2
Eye irritation, category 2
Skin sensitisation, category 1
Specific Target Organ Toxicity – Single exposure, category 3
GHS08
Respiratory sensitization, category 1
Germ cell mutagenicity, categories 1A,1B,2
Carcinogenicity, categories 1A,1B,2
Reproductive toxicity, categories 1A,1B,2
Specific Target Organ Toxicity – Single exposure, categories 1,2
Specific Target Organ Toxicity – Repeated exposure, categories 1,2
Aspiration Hazard, category 1
GHS Signal Word
Danger
European Hazard Symbols
Toxic Toxic (T)
German water hazard class
3
Personal Protective Equipment
Eyeshields, Faceshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges
GHS Precautionary statements
P201-P308+P313
Risk Statements
60-61-22
Storage Temperature
-20°C
RTECS
UK8000000
Safety Statements
53-22-26-36/37/39-45
Pharmacology Properties
Gene Information
human ... PTGER1(5731), PTGER2(5732), PTGER3(5733), PTGER4(5734), PTGIR(5739)mouse ... Ptger1(19216), Ptger2(19217), Ptger3(19218), Ptger4(19219)
Physical Property
Apperance
powder
Molecule Details
Physical form
powder -20 °C; stock-frozen in working aliquots, avoid repeated freeze/thaw
Biochem/physiol Actions
Most biologically active prostaglandin. PGE2 induces cervical ripening and parturition; mediates bradykinin-induced vasodilation; regulates adenylyl cyclase. Tumor cells that over-express cyclooxygenase 2 display increased invasiveness, angiogenesis, and resistance to apoptosis that may be due to the PGE2-induced expression of angiogenic factors and stabilization of the anti-apoptotic protein, survivin.The effect of PGE2 on the immune system is mixed. It inhibits T cell activation in vitro, suggesting it is an immunosuppressant. However, in vivo, it appears to effect expansion of the Th17 subset and differentiation of the Th1 subset of T helper cells, marking it as an immunoactivator.1
Prostaglandin E2 is a signaling molecule produced by activated platelets. The release of PGE2 by activated platelets is part of a mechanism by which activated platelets utilize adjacent erythrocytes to help in clot formation. This product was shown to lower the filterability of human erythrocytes by approximately 30% at a concentration of 10-10sup M and also caused a reduction in mean cell volume by about 10%. The cause of cell shrinkage was the induction of a PGE2- stimulated K+ efflux pathway leading to rapid loss of cellular K+ ions. This loss was shown to be Ca2+dependent. PGE2 has been shown to stimulate the production of interleukin-6 (IL-6) by neonatal mouse parietal bones. After 6 hours in culture, cells stimulated with 10-8sup M PGE2 produced significantly more IL-6 than controls. The pyrogenic activity of PGE2 was not inhibited by dexamethasone, unlike prostaglandin F2α.Most biologically active prostaglandin. PGE2 induces cervical ripening and parturition; mediates bradykinin-induced vasodilation; regulates adenylyl cyclase. Tumor cells that over-express cyclooxygenase 2 display increased invasiveness, angiogenesis, and resistance to apoptosis that may be due to the PGE2-induced expression of angiogenic factors and stabilization of the anti-apoptotic protein, survivin.
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data